Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Capital Expenditures (2017 - 2025)

Crinetics Pharmaceuticals has reported Capital Expenditures over the past 9 years, most recently at $5.7 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $5.7 million for Q4 2025, up 4734.75% from a year ago — trailing twelve months through Dec 2025 was $5.8 million (up 3101.11% YoY), and the annual figure for FY2025 was $5.8 million, up 3101.11%.
  • Capital Expenditures for Q4 2025 was $5.7 million at Crinetics Pharmaceuticals, up from -$30000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for CRNX hit a ceiling of $5.7 million in Q4 2025 and a floor of -$2.2 million in Q3 2024.
  • Median Capital Expenditures over the past 5 years was $82000.0 (2022), compared with a mean of $669578.9.
  • Biggest five-year swings in Capital Expenditures: plummeted 275.0% in 2021 and later soared 16981.82% in 2023.
  • Crinetics Pharmaceuticals' Capital Expenditures stood at $18000.0 in 2021, then skyrocketed by 8766.67% to $1.6 million in 2022, then crashed by 41.42% to $935000.0 in 2023, then tumbled by 87.38% to $118000.0 in 2024, then soared by 4734.75% to $5.7 million in 2025.
  • The last three reported values for Capital Expenditures were $5.7 million (Q4 2025), -$30000.0 (Q3 2025), and -$177000.0 (Q2 2025) per Business Quant data.